大成生化科技(00809.HK)與合肥和晨訂立戰略合作協議 共同推進合成生物技術在氨基酸領域產業化應用
格隆匯5月23日丨大成生化科技(00809.HK)公告，於2025年5月20日，集團參加由長春經濟技術開發區管委會與長春市股權投資基金管理有限公司共同舉辦的長春經開區合成生物產業創新發展先導區啓動大會，於大會上，公司全資附屬公司長春鴻成生物化工材料技術開發有限公司("鴻成生物技術")，與在中華人民共和國("中國")成立的合肥和晨生物科技有限公司("合肥和晨")，訂立戰略合作框架協議。
作爲大會議程之一，鴻成生物技術與合肥和晨訂立戰略合作框架協議，據此，彼等將利用雙方在合成生物學領域的各自優勢，聚焦吉林省重點產業相關應用，支持該省生物製造產業發展。具體而言，戰略合作旨在將集團在技術規模化、工藝優化、生產流程設計及成本控制等方面的經驗，與合肥和晨在合成生物學領域的優勢(包括基因設計、菌種構建及代謝途徑優化等技術)相結合，共同推進合成生物技術在氨基酸領域的產業化應用，從而增強雙方的市場競爭力。
根據目前的戰略合作計劃，集團及合肥和晨將利用位於集團興隆山生產基地的研究中心及中試設施("研發設施")以建立併合作營運合成生物中試平臺。興隆山生產基地的研發設施包括約10,000平方米的工廠及廠房，連同生化、生物發酵、食品及動物保護四個研究和發展中心。其亦設有一個生物發酵產品試驗廠房，配備七個生物化學品中試設施。
於簽訂戰略合作框架協議後，中試平臺揭牌儀式於大會期間順利舉行，標誌着技術成果轉化爲產業化成果進程中的"最後一公里"橋接完成，助力生物基化學品、醫療材料及其他相關領域的產業化突破。
合肥和晨爲一間於中國成立的有限公司。其主要從事將合成生物學與前沿遞送技術相結合，並專注於開發生物基化學品、特殊的氨基酸及高附加值活性成分等原料產品。其亦利用高附加值活性成分及前沿遞送技術推出美容產品及功能食品應用解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
